文献速递膀胱癌与上尿路尿路上皮癌

PURE-01更新5年生存结果:新辅助帕博利珠单抗后根治性膀胱切除术

Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol · 2026-02-03

PURE-01研究评估3周期帕博利珠单抗200 mg后根治性膀胱切除术治疗cT2-3bN0M0肌层浸润性膀胱癌(MIBC)患者,共155例。中位随访>60个月,5年无事件生存率68%,5年总生存率77%。病理缓解与生存显著相关,完全或主要缓解组5年OS率约90%。

要点

  • 5年OS率77%,5年EFS率68%,5年RFS率77%
  • 完全或主要病理缓解组5年OS率约90%
  • claudin-low亚型5年RFS率最高,5年OS率93%

核心结论

  • PURE-01长期随访显示持续生存获益,病理缓解和分子亚型具有预后相关性。

研究设计与样本

  • 2期研究,155例cT2-3bN0M0 MIBC患者接受3周期帕博利珠单抗200 mg后根治性膀胱切除术。

主要发现

  • 意向治疗人群5年无事件生存率68%,5年总生存率77%。
  • 根治性膀胱切除术队列5年无复发生存率77%。
  • 病理缓解类别与生存显著相关,完全或主要缓解组5年OS率约90%(p<0.001)。
  • 5年累积复发风险19%,31例复发中3例发生在术后5年以上。
  • 8例拒绝根治性膀胱切除术接受经尿道切除术,其中7例存活且无病。

关键数值与推荐

  • 预处理组织转录组分析可评估102例,claudin-low亚型(n=14)5年RFS率最高,5年OS率93%。

临床怎么用

  • 支持在特定患者中进一步研究单药免疫治疗作为降阶梯策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The PURE-01 trial evaluated three cycles of pembrolizumab 200 mg followed by radical cystectomy (RC) in patients with cT2-3b N0 M0 muscle-invasive bladder cancer (MIBC) ineligible for or refusing cisplatin. A total of 155 patients were treated. We report survival outcomes after median follow-up of >60 mo and associations with pathological response rates and biomarker levels. In the intention-to-treat population, the 5-yr event-free survival rate was 68% and the 5-yr overall survival (OS) rate was 77%. In the RC cohort, the 5-yr recurrence-free survival (RFS) rate was 77%. Pathological response categories were significantly associated with survival, with a 5-yr OS rate of ∼90% in the group achieving a complete or major response (p < 0.001). The 5-yr cumulative risk of recurrence was 19%, with three of 31 relapses occurring beyond 5 yr after RC. Eight patients refused RC and underwent transurethral resection; seven remain alive and disease-free. Transcriptome-wide profiling of pretreatment tissue was available for 102 patients. Stratification by genomic subtyping classifier showed that the claudin-low subtype (n = 14) had the highest 5-yr RFS rate, with a 5-yr OS rate of 93%. At long-term follow-up, PURE-01 demonstrates sustained survival outcomes and confirms the prognostic relevance of pathological response and molecular subtypes. These results support further investigation of single-agent immunotherapy as a potential de-escalation strategy in selected patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Tateo V, Basile G, Giannatempo P, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. 2026. PMID: 41633898. doi:10.1016/j.eururo.2026.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。